KR20230147131A - Hiv 인테그라제 억제제로서 유용한 테트라시클릭 헤테로사이클 화합물 - Google Patents

Hiv 인테그라제 억제제로서 유용한 테트라시클릭 헤테로사이클 화합물 Download PDF

Info

Publication number
KR20230147131A
KR20230147131A KR1020237031339A KR20237031339A KR20230147131A KR 20230147131 A KR20230147131 A KR 20230147131A KR 1020237031339 A KR1020237031339 A KR 1020237031339A KR 20237031339 A KR20237031339 A KR 20237031339A KR 20230147131 A KR20230147131 A KR 20230147131A
Authority
KR
South Korea
Prior art keywords
hiv
pharmaceutically acceptable
compound
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031339A
Other languages
English (en)
Korean (ko)
Inventor
티모시 존 하르팅
존 에이. 맥컬리
타오 유
용리안 장
Original Assignee
머크 샤프 앤드 돔 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 엘엘씨 filed Critical 머크 샤프 앤드 돔 엘엘씨
Publication of KR20230147131A publication Critical patent/KR20230147131A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020237031339A 2021-02-16 2022-02-14 Hiv 인테그라제 억제제로서 유용한 테트라시클릭 헤테로사이클 화합물 Pending KR20230147131A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
US63/149,927 2021-02-16
PCT/US2022/016261 WO2022177840A1 (en) 2021-02-16 2022-02-14 Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
KR20230147131A true KR20230147131A (ko) 2023-10-20

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031339A Pending KR20230147131A (ko) 2021-02-16 2022-02-14 Hiv 인테그라제 억제제로서 유용한 테트라시클릭 헤테로사이클 화합물

Country Status (12)

Country Link
US (1) US11958864B2 (cg-RX-API-DMAC7.html)
EP (1) EP4294813B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507788A (cg-RX-API-DMAC7.html)
KR (1) KR20230147131A (cg-RX-API-DMAC7.html)
CN (1) CN117083282B (cg-RX-API-DMAC7.html)
AR (1) AR124868A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022223241B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208396A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048138T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009445A (cg-RX-API-DMAC7.html)
TW (1) TW202246286A (cg-RX-API-DMAC7.html)
WO (1) WO2022177840A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024226485A1 (en) * 2023-04-28 2024-10-31 Merck Sharp & Dohme Llc Delivery devices for anti-hiv compounds
WO2026101812A1 (en) * 2024-11-07 2026-05-15 Merck Sharp & Dohme Llc Hiv integrase inhibitors for treatment of hiv infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
LT2620436T (lt) * 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018140368A1 (en) * 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
WO2022177840A1 (en) 2022-08-25
CN117083282A (zh) 2023-11-17
ES3048138T3 (en) 2025-12-09
JP2024507788A (ja) 2024-02-21
CA3208396A1 (en) 2022-08-25
CN117083282B (zh) 2026-05-29
AR124868A1 (es) 2023-05-10
US11958864B2 (en) 2024-04-16
EP4294813A1 (en) 2023-12-27
AU2022223241B2 (en) 2026-04-30
US20220259227A1 (en) 2022-08-18
AU2022223241A1 (en) 2023-08-24
MX2023009445A (es) 2023-08-25
TW202246286A (zh) 2022-12-01
EP4294813B1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
EP4294813B1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3752144B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CA3232906A1 (en) Pi3k-alpha inhibitors and methods of use thereof
KR20210005139A (ko) Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
EP3377065B1 (en) Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
US11884683B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
EP3548031B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016187788A1 (en) Fused tricyclic heterocyclic compounds useful for treating hiv infection
KR20180095833A (ko) Hiv 인테그라제 억제제로서의 융합된 트리시클릭 헤테로시클릭 화합물
JP2019536791A (ja) Hivインテグラーゼ阻害剤として有用な四環式複素環化合物
US10786488B2 (en) Substituted quinolizine derivatives useful as HIV integrase inhibitors
CN120607543A (zh) 胺基取代芳杂环类抑制剂及其制备方法和应用
RU2851203C2 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
EP2646445A1 (en) Oxazolo [5, 4 -b]pyridin- 5 -yl compounds and their use for the treatment of cancer
US20210115044A1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230913

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250212

Comment text: Request for Examination of Application